Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients

Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer., 19, 133, 10.1038/s41568-019-0116-x Herbst, 2018, The biology and management of non-small cell lung cancer, Nature., 553, 446, 10.1038/nature25183 Planchard, 2018, P.E. Van Schil, M.D. Hellmann, S. Peters, Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv192, 10.1093/annonc/mdy275 Gray, 2020, Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC, J. Thorac. Oncol., 15, 288, 10.1016/j.jtho.2019.10.002 Seymour, 2017, RECIST working group, iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics, Lancet. Oncol., 18, e143, 10.1016/S1470-2045(17)30074-8 Postow, 2018, Immune-related adverse events associated with immune checkpoint blockade, N. Engl. J. Med., 378, 158, 10.1056/NEJMra1703481 Zhang, 2020, The progress and confusion of anti-PD1/PD-L1 immunotherapy for patients with advanced non-small cell lung cancer, Int. Immunopharmacol., 80, 10.1016/j.intimp.2020.106247 Buttner, 2017, Programmed death-ligand 1 immunohistochemistry testing: A review of analytical assays and clinical implementation in non-small-cell lung cancer, J. Clin. Oncol., 35, 3867, 10.1200/JCO.2017.74.7642 Rizvi, 2015, Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science (80-. ), 348, 124, 10.1126/science.aaa1348 Corredor, 2019, Spatial architecture and arrangement of tumor-infiltrating lymphocytes for predicting likelihood of recurrence in early-stage non–small cell lung cancer, Clin. Cancer Res., 25, 1526, 10.1158/1078-0432.CCR-18-2013 Mazzaschi, 2018, Low PD-1 expression in cytotoxic CD8 þ tumor-Infiltrating lymphocytes confers an immune-privileged tissue microenvironment in NSCLC with a prognostic and predictive value, Clin. Cancer Res., 24, 407, 10.1158/1078-0432.CCR-17-2156 Hu-Lieskovan, 2019, Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer, Clin. Cancer Res., 10.1158/1078-0432.CCR-18-4275 Danaher, 2018, Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): Results from The Cancer Genome Atlas (TCGA), J. Immunother. Cancer., 6, 1, 10.1186/s40425-018-0367-1 Binnewies, 2018, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nat. Med., 24, 541, 10.1038/s41591-018-0014-x Tsao, 2018, PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project, J. Thorac. Oncol., 13, 1302, 10.1016/j.jtho.2018.05.013 Abu Hejleh, 2019, The clinical significance of soluble PD-1 and PD-L1 in lung cancer, Crit. Rev. Oncol. Hematol., 143, 148, 10.1016/j.critrevonc.2019.08.009 Costantini, 2018, Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab, Oncoimmunology., 7 Vecchiarelli, 2018, Circulating programmed death ligand-1 (cPD-L1) in non-smallcell lung cancer (NSCLC), Oncotarget, 9, 17554, 10.18632/oncotarget.24785 Okuma, 2017, High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer, Lung Cancer., 104, 1, 10.1016/j.lungcan.2016.11.023 Okuma, 2018, Soluble Programmed Cell Death Ligand 1 as a Novel Biomarker for Nivolumab Therapy for Non–Small-cell Lung Cancer, Clin. Lung Cancer., 19, 410, 10.1016/j.cllc.2018.04.014 Kargl, 2017, A.M. McGarry Houghton, Neutrophils dominate the immune cell composition in non-small cell lung cancer, Nat. Commun., 8, 1, 10.1038/ncomms14381 Mezquita, 2018, Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer, JAMA Oncol., 4, 351, 10.1001/jamaoncol.2017.4771 Kazandjian, 2019, Prognostic Value of the Lung Immune Prognostic Index for Patients Treated for Metastatic Non-Small Cell Lung Cancer, JAMA Oncol., 5, 1481, 10.1001/jamaoncol.2019.1747 Mazzaschi, 2019, The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC, Lung Cancer., 127, 153, 10.1016/j.lungcan.2018.11.038 Bodduluru, 2015, Natural killer cells: The journey from puzzles in biology to treatment of cancer, Cancer Lett., 357, 454, 10.1016/j.canlet.2014.12.020 Kamphorst, 2017, Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients, Proc. Natl. Acad. Sci. U. S. A., 114, 4993, 10.1073/pnas.1705327114 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur. J. Cancer., 45, 228, 10.1016/j.ejca.2008.10.026 Lantuejoul, 2020, PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee, J. Thorac. Oncol., 15, 499, 10.1016/j.jtho.2019.12.107 Schemper, 1996, A note on quantifying follow-up in studies of failure time, Control. Clin. Trials., 17, 343, 10.1016/0197-2456(96)00075-X 2020 Hanna, 2020, Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update, J. Clin. Oncol., 10.1200/JCO.19.03022 Leonetti, 2019, Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer, Drug Resist. Updat., 46, 10.1016/j.drup.2019.100644 Tray, 2018, Predictive biomarkers for checkpoint immunotherapy: Current status and challenges for clinical application, Cancer Immunol. Res., 6, 1122, 10.1158/2326-6066.CIR-18-0214 Fumet, 2020, Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts, Eur. J. Cancer., 131, 40, 10.1016/j.ejca.2020.02.038 Hernandez, 2020, 1 Ugurel, 2020, Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma, Ann. Oncol., 31, 144, 10.1016/j.annonc.2019.09.005 Frigola, 2011, Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma, Clin. Cancer Res., 17, 1915, 10.1158/1078-0432.CCR-10-0250 Schmidt, 2019, Enhanced adaptive immune responses in lung adenocarcinoma through natural killer cell stimulation, Proc. Natl. Acad. Sci. U. S. A., 116, 17460, 10.1073/pnas.1904253116 Facchinetti, 2018, Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab, Immunotherapy., 10, 681, 10.2217/imt-2017-0175 Kargl, 2019, Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC, JCI Insight., 4, 1, 10.1172/jci.insight.130850 Takada, 2020, Serum markers associated with treatment response and survival in non-small cell lung cancer patients treated with anti-PD-1 therapy, Lung Cancer., 145, 18, 10.1016/j.lungcan.2020.04.034